Summit Therapeutics Inc. Stock

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-14 pm EDT 5-day change 1st Jan Change
8.39 USD +3.71% Intraday chart for Summit Therapeutics Inc. +8.68% +221.46%
Sales 2024 * - Sales 2025 * - Capitalization 4.64B 5.89B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 105
Yield 2024 *
-
Yield 2025 *
-
Free-Float 11.86%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Summit Therapeutics Inc.

1 day+3.71%
1 week+8.68%
Current month-3.40%
1 month+79.08%
3 months+76.63%
6 months+217.80%
Current year+221.46%
More quotes
1 week
7.52
Extreme 7.52
8.48
1 month
2.10
Extreme 2.1
11.25
Current year
2.10
Extreme 2.1
11.25
1 year
1.52
Extreme 1.52
11.25
3 years
0.66
Extreme 0.66
11.25
5 years
0.66
Extreme 0.66
12.30
10 years
0.66
Extreme 0.66
19.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 20-11-10
Chief Executive Officer 79 19-11-30
Director of Finance/CFO 46 19-11-30
Members of the board TitleAgeSince
Chief Executive Officer 79 19-11-30
Director/Board Member 70 22-09-27
Director of Finance/CFO 46 19-11-30
More insiders
Date Price Change Volume
24-06-14 8.39 +3.71% 1,870,845
24-06-13 8.09 -1.94% 1,875,109
24-06-12 8.25 +9.42% 4,355,243
24-06-11 7.54 -5.51% 2,681,423
24-06-10 7.98 +3.37% 3,120,567

Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT

More quotes
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.616 GBP
Average target price
10.58 GBP
Spread / Average Target
+59.94%
Consensus

Quarterly revenue - Rate of surprise